| Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial J Chataway, F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, ... The Lancet Neurology 19 (3), 214-225, 2020 | 111 | 2020 |
| Disease-modifying therapies for multiple sclerosis F De Angelis, NA John, WJ Brownlee bmj 363, 2018 | 109 | 2018 |
| Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era DS Lynch, C Wade, ARB De Paiva, N John, JA Kinsella, Á Merwick, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (5), 543-555, 2019 | 102 | 2019 |
| Is general anaesthesia preferable to conscious sedation in the treatment of acute ischaemic stroke with intra-arterial mechanical thrombectomy? A review of the literature N John, P Mitchell, R Dowling, B Yan Neuroradiology 55, 93-100, 2013 | 65 | 2013 |
| Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing … P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John, ... BMJ open 8 (8), e021944, 2018 | 54 | 2018 |
| Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis A Calvi, FP Carrasco, C Tur, DT Chard, J Stutters, F De Angelis, N John, ... Neurology 98 (17), e1783-e1793, 2022 | 37 | 2022 |
| Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, N John, ... Efficacy and Mechanism Evaluation 7 (3), 1-72, 2020 | 16 | 2020 |
| Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, ... JAMA neurology 80 (7), 702-713, 2023 | 15 | 2023 |
| NAA is a marker of disability in secondary-progressive MS: A proton MR spectroscopic imaging study BS Solanky, NA John, F DeAngelis, J Stutters, F Prados, T Schneider, ... American Journal of Neuroradiology 41 (12), 2209-2218, 2020 | 15 | 2020 |
| Multiple sclerosis and demyelinating diseases S Leary, W Brownlee, N Barker, D Chard, J Chataway, K Chung, ... Neurology: a Queen square textbook, 603-654, 2024 | 11 | 2024 |
| Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, ... JAMA neurology 80 (8), 789-797, 2023 | 11 | 2023 |
| UK Multiple Sclerosis Society Clinical Trials Network P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS …, 2018 | 6 | 2018 |
| A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis I Roos, S Hughes, G MacDonnell, C Boz, R Alroughani, S Ozakbas, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 951-953, 2022 | 5 | 2022 |
| Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis N John, A Carroll, WJ Brownlee, J Chataway Journal of Neurology, Neurosurgery & Psychiatry 90 (12), 1376-1378, 2019 | 5 | 2019 |
| Urinary tract infection in multiple sclerosis: closing an audit loop by co-design and innovation B Porter, NA John, R Brenner, HC Wilson, B Turner, J Chataway British Journal of Neuroscience Nursing 15 (1), 20-27, 2019 | 5 | 2019 |
| MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in … J Chataway, F De Angelis, P Connick, R Parker, D Plantone, A Doshi, ... MULTIPLE SCLEROSIS JOURNAL 24, 986-987, 2018 | 5 | 2018 |
| Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, ... Multiple Sclerosis Journal 29 (7), 875-883, 2023 | 4 | 2023 |
| Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, R Alroughani, ... SAGE PUBLICATIONS LTD, 2022 | 4 | 2022 |
| Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: validation of an updated algorithm F O'Herlihy, NA John, V Li, B Porter, L Lyons, M Rakusa, C Curtis, ... Journal of the Neurological Sciences 407, 116456, 2019 | 4 | 2019 |
| TP1-11 MS-STAT2: a phase 3 trial of high dose simvastatin in secondary progressive multiple sclerosis E Williams, NA John, J Blackstone, W Brownlee, C Frost, J Greenwood, ... Journal of Neurology, Neurosurgery and Psychiatry 90 (3), e13, 2019 | 4 | 2019 |
